The CRL allowed its junior competitor Sangamo to catch up with its own gene therapy for Hemophilia A. The investment thesis here is that the CRL is resolvable ...
https://www.google.com/url?rct=j&sa=t&url=https://seekingalpha.com/article/4450409-biomarin-is-highly-attractive-for-longer-term-investors&ct=ga&cd=CAIyGmEyNDJjNTAxZWU3OTQyNzI6Y29tOmVuOlVT&usg=AFQjCNGHxdgdWHGMJol0kjglikmyog_HnQ
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.